Antibe Analyst Call – Positive Phase IIB Dose-Ranging, Efficacy Results
June 4, 2020 | Conference Call
Antibe hosted a conference call to discuss the recent positive results of the Phase IIB dose-ranging, efficacy study for otenaproxesul (ATB-346). Management provided a brief summary of the results which was followed by a Q&A session for analysts. Please click on the “Read” link below to listen to an audio replay of the call.